Aktiesnakken — Februar 2011
-
ja
-
var det inden gsk aftalen?
-
for umiddelbart har lundbeck da performede bedre?
-
indtil videre vil markedet ikke lege med ihvertfald, men turnarounden skete vel ret beset med GSK aftalen
-
med penge i kassen + loft over udgifterne
-
alt i orden nrsb
-
ja det er jo nye koste...i genmab, men under lisa kom det altid efter luk
-
159-160
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind